| Bioactivity | Pamoic acid is a potent GPR35 agonist with an EC50 of 79 nM. Pamoic acid exhibits neuroprotective and anti-inflammatory properties[1][2]. |
| Target | EC50: 79 nM (GPR35) |
| Invitro | GPR35 activation by Pamoic acid may increase the phosphorylation of ERK1/2, which in turn initiates an anti-inflammatory signal by suppressing NF-κB-dependent inflammatory genes[1]. |
| In Vivo | In a mouse model of stroke, that GPR35 activation by Pamoic acid (s.c.; 50-100 mg/kg) is neuroprotective. Pharmacological inhibition of GPR35 reveals that Pamoic acid reduces infarcts size in a GPR35 dependent manner. Pamoic acid treatment results in a preferential increment of noninflammatory Ly-6CLo monocytes/macrophages in the ischemic brain along with the reduced neutrophil counts[1]. |
| Name | Pamoic acid |
| CAS | 130-85-8 |
| Formula | C23H16O6 |
| Molar Mass | 388.38 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen) |
| Reference | [1]. Ozayra Sharmin, et al. Activation of GPR35 protects against cerebral ischemia by recruiting monocyte-derived macrophages. Sci Rep. 2020 Jun 10;10(1):9400. [2]. Pingwei Zhao, et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol. 2010 Oct;78(4):560-8. |